ES2989975T3 - Anticuerpos contra el antígeno de células madre específico de la próstata y su uso - Google Patents

Anticuerpos contra el antígeno de células madre específico de la próstata y su uso Download PDF

Info

Publication number
ES2989975T3
ES2989975T3 ES18207370T ES18207370T ES2989975T3 ES 2989975 T3 ES2989975 T3 ES 2989975T3 ES 18207370 T ES18207370 T ES 18207370T ES 18207370 T ES18207370 T ES 18207370T ES 2989975 T3 ES2989975 T3 ES 2989975T3
Authority
ES
Spain
Prior art keywords
seq
psca
antibody
variable region
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18207370T
Other languages
English (en)
Spanish (es)
Inventor
Michael Bachmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avencell Europe GmbH
Original Assignee
Avencell Europe GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avencell Europe GmbH filed Critical Avencell Europe GmbH
Application granted granted Critical
Publication of ES2989975T3 publication Critical patent/ES2989975T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES18207370T 2011-06-30 2012-06-29 Anticuerpos contra el antígeno de células madre específico de la próstata y su uso Active ES2989975T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102011118022.6A DE102011118022B4 (de) 2011-06-30 2011-06-30 Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Publications (1)

Publication Number Publication Date
ES2989975T3 true ES2989975T3 (es) 2024-11-28

Family

ID=46384405

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18207370T Active ES2989975T3 (es) 2011-06-30 2012-06-29 Anticuerpos contra el antígeno de células madre específico de la próstata y su uso
ES12729996T Active ES2711978T3 (es) 2011-06-30 2012-06-29 Anticuerpos contra el antígeno de células madre específico de la próstata y su uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12729996T Active ES2711978T3 (es) 2011-06-30 2012-06-29 Anticuerpos contra el antígeno de células madre específico de la próstata y su uso

Country Status (18)

Country Link
US (1) US9200078B2 (OSRAM)
EP (2) EP3505536B1 (OSRAM)
JP (4) JP2014528696A (OSRAM)
AU (1) AU2012277784B2 (OSRAM)
CY (1) CY1121249T1 (OSRAM)
DE (1) DE102011118022B4 (OSRAM)
DK (1) DK2726507T3 (OSRAM)
ES (2) ES2989975T3 (OSRAM)
HR (1) HRP20190289T1 (OSRAM)
HU (1) HUE042008T2 (OSRAM)
LT (1) LT2726507T (OSRAM)
PL (1) PL2726507T3 (OSRAM)
PT (1) PT2726507T (OSRAM)
RS (1) RS58448B1 (OSRAM)
SI (1) SI2726507T1 (OSRAM)
SM (1) SMT201900085T1 (OSRAM)
TR (1) TR201901991T4 (OSRAM)
WO (1) WO2013001065A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
MA53293A (fr) 2018-08-08 2021-11-17 Dragonfly Therapeutics Inc Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
AU2021276327A1 (en) * 2020-05-19 2022-12-01 City Of Hope Engineered anti-prostate stem cell antigen fusion proteins and uses thereof
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
WO2024233662A2 (en) * 2023-05-09 2024-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to psca polypeptides
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
WO1998040403A1 (en) * 1997-03-10 1998-09-17 The Regents Of The University Of California Psca: prostate stem cell antigen
DK1226177T3 (da) * 1999-10-29 2008-10-06 Genentech Inc Antistofsammensætninger mod anti-prostata stamcelle-antigen (PSCA) og anvendelser deraf
KR101229731B1 (ko) * 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 다중특이적 탈면역화된 ｃｄ3-바인더
JP4651663B2 (ja) * 2004-05-28 2011-03-16 アジェンシス，インコーポレイテッド Ｐｓｃａタンパク質に結合する抗体および関連分子
CA2698343C (en) * 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
BRPI0919840B1 (pt) * 2008-10-01 2023-02-28 Amgen Research (Munich) Gmbh Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
US20110142811A1 (en) * 2009-12-16 2011-06-16 Deutsches Krebsforschungszentrum Measles virus for the elimination of unwanted cell populations
DE102011118022B4 (de) * 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung

Also Published As

Publication number Publication date
RS58448B1 (sr) 2019-04-30
PL2726507T3 (pl) 2019-06-28
ES2711978T3 (es) 2019-05-08
JP6886491B2 (ja) 2021-06-16
LT2726507T (lt) 2019-04-10
US20140134155A1 (en) 2014-05-15
JP2021121201A (ja) 2021-08-26
AU2012277784B2 (en) 2015-08-20
SI2726507T1 (sl) 2019-05-31
EP2726507B1 (de) 2018-11-21
DE102011118022B4 (de) 2018-01-18
HRP20190289T1 (hr) 2019-05-03
JP2014528696A (ja) 2014-10-30
EP3505536A1 (de) 2019-07-03
DE102011118022A1 (de) 2013-01-03
DK2726507T3 (en) 2019-03-11
WO2013001065A1 (de) 2013-01-03
US9200078B2 (en) 2015-12-01
JP7341185B2 (ja) 2023-09-08
JP6549622B2 (ja) 2019-07-24
PT2726507T (pt) 2019-02-26
HUE042008T2 (hu) 2019-06-28
EP3505536B1 (de) 2024-08-07
AU2012277784A1 (en) 2014-02-06
TR201901991T4 (tr) 2019-03-21
CY1121249T1 (el) 2020-05-29
EP2726507A1 (de) 2014-05-07
EP3505536C0 (de) 2024-08-07
JP2019193652A (ja) 2019-11-07
JP2017104113A (ja) 2017-06-15
SMT201900085T1 (it) 2019-05-10

Similar Documents

Publication Publication Date Title
ES2989975T3 (es) Anticuerpos contra el antígeno de células madre específico de la próstata y su uso
KR102749049B1 (ko) 분자를 표적화하기 위한 항원 결합 구조체
ES2523502T3 (es) Anticuerpos anti-CD33 y su aplicación para el inmunotargeting en el tratamiento de enfermedades asociadas a CD33
US11414497B2 (en) Anti-PSMA antibodies and use thereof
ES2924722T3 (es) Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3
ES2255050T3 (es) Vectores de expresion que codifican proteinas de fusion biespecificas biologicamente activas en celulas de mamiferos.
ES2963561T3 (es) Anticuerpo de unión a PSMA y usos del mismo
ES2751996T3 (es) Moléculas de unión para BCMA y CD3
BR112019020168A2 (pt) Receptores de ligação ao antígeno, células t transduzidas, polinucleotídeo isolado, vetor, kits, métodos para tratar uma doença e para induzir a lise de uma célula alvo e uso do receptor de ligação ao antígeno
BRPI0620632A2 (pt) composições farmacêuticas com resistência a cea solúvel, processo de produção das mesmas, usos de anticorpo bi-especìfico de cadeia simples, molécula de ácido nucléico, vetor e hospedeiro na preparação de composição farmacêuticas, e kits
CN112175085B (zh) 抗gpc3抗体及其用途
WO2023143535A1 (zh) 一种靶向il-18bp的抗体及其应用
CN110352197B (zh) 嵌合氯毒素受体
ES2831651T3 (es) Uso de anticuerpos y antagonistas dirigidos contra Lrg1 en un tratamiento
WO2023133842A1 (zh) 一种靶向IL-18Rβ的抗体及其应用
ES2975798T3 (es) Anticuerpos contra antígeno carcinoembrionario para tratamiento y diagnóstico de cáncer
HK1197419A (en) Antibodies against prostate-specific stem cell antigen and use thereof
KR20220143904A (ko) 사람 4-1bb 항진제 항체 및 이의 사용 방법
CN118119643A (zh) 靶向bcma的组合物及其使用方法
HK1197419B (en) Antibodies against prostate-specific stem cell antigen and use thereof
HK1255107B (en) Antigen binding constructs to target molecules